

UCSF

UC San Francisco Previously Published Works

Title

Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives.

Permalink

<https://escholarship.org/uc/item/3kq257cs>

Journal

Clinical Journal of the American Society of Nephrology

ISSN

1555-9041

Authors

Yerram, Preethi

Brazie, Marc

Edwards, Dawn P

et al.

Publication Date

2026-09-14

DOI

10.2215/cjn.0000001250

Peer reviewed

Clinical Journal of the American Society of Nephrology

Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives

--Manuscript Draft--

Manuscript Number:	CJASN-2026-000926R1
Full Title:	Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives
Short Title:	Emotional Landscape of Kidney Allograft Failure
Article Type:	Perspective - Invited
Corresponding Author:	Preethi Yerram, MD University of Missouri Columbia Health Care: MU Health Care, '8' Harry S Truman VA Hospital columbia, Missouri UNITED STATES
Corresponding Author E-Mail:	yerramp@health.missouri.edu
Other Authors:	Marc Brazie, MD Dawn P. Edwards Andrew Howard, MD Daniel Landry, DO Precious McCowan, PhD, MS Ramin Sam, MD Renata Sledge, PhD, LCSW Mary Baliker, BS
Order of Authors (with Contributor Roles):	Preethi Yerram, MD, MS (Conceptualization; Writing – original draft; Writing – review & editing) Marc Brazie, MD (Writing – original draft; Writing – review & editing) Dawn P. Edwards (Writing – original draft; Writing – review & editing) Andrew Howard, MD (Writing – original draft; Writing – review & editing) Daniel Landry, DO (Writing – original draft; Writing – review & editing) Precious McCowan, PhD, MS (Writing – original draft; Writing – review & editing) Ramin Sam, MD (Writing – original draft; Writing – review & editing) Renata Sledge, PhD, LCSW (Writing – original draft; Writing – review & editing) Mary Baliker, BS (Conceptualization; Writing – original draft; Writing – review & editing)
Manuscript Classifications:	Acute Allograft Rejection; Acute Rejection; Chronic Rejection; Kidney Transplantation; Organ Transplant; Rejection; Renal Transplantation; Transplantation
Funding Information:	
Additional Information:	
Question	Response

Title: Navigating the Emotional Landscape of Kidney Allograft Failure

Subtitle: Patient and Provider Perspectives

Preethi Yerram MD, MS^{1,2}, Marc Brazie MD³, Dawn P. Edwards⁴, Andrew Howard MD³,
Daniel Landry DO⁵, Precious McCowan PhD, MS⁴, Ramin Sam MD⁶, Renata Sledge PhD, LCSW⁷,
Mary Baliker BS⁴

Harry S Truman VA Hospital, Columbia Missouri¹; University of Missouri-Columbia, Columbia,
Missouri²,

Metropolitan Nephrology Associates, Clinton, Maryland³

The National Forum of ESRD Networks, Henrico, Virginia⁴

University of Massachusetts Chan Medical School-Baystate Campus: Baystate Medical Center,
Springfield, Massachusetts⁵

Zuckerberg San Francisco General Hospital, University of California, San Francisco, California⁶

University of Missouri-St Louis, St Louis, Missouri⁷

Corresponding Author

Preethi Yerram MD, MS

1 Hospital Dr,

Columbia, MO 65203

yerramp@health.missouri.edu

5738827992

Introduction

Kidney transplantation is the preferred treatment for end-stage kidney disease (ESKD), improving survival and quality of life. Yet, allograft failure is common, a clinically and emotionally difficult journey for patients and care teams alike. Recognizing this shared burden, the Forum of ESRD Networks invited patients, and physicians from the Kidney Patient Advisory Council (KPAC) and Medical Advisory Council (MAC) to share written reflections on graft failure, edited for length and clarity with authors' approval. Through these narratives, we hope to encourage continued clinical and research attention to the emotional aspects of kidney allograft failure.

Patient Experience

Patient voice #1: Guilt, Hopelessness, Building resilience

"Living with kidney disease since childhood, I've received the "gift of life" through four transplants, but the journey has been a rollercoaster. I'll never forget my doctor entering the room, eyes downcast, to deliver the news: "The kidney is rejecting." It felt like the air left the room. After eleven years with my third transplant, I was shattered: "Would I return to dialysis?"
"What did I do wrong?"

I moved from asking "why me" to "what now," embracing resilience over despair. This determination carried me through the loss until I received a fourth chance at life. Yet, I live with the constant, uncertainty of "what if this kidney fails too?" Supported by family and friends, taking it one day at a time is my only path forward, balancing gratitude with fear of the unknown. Repeated loss does not build immunity to the pain; each failure makes the emotional burden harder to endure."

Patient voice #2: Emotional exhaustion, Disappointment, Making peace

"As a patient living with kidney disease for 35 years, I thought I was prepared for anything. Having experienced multiple treatment modalities, I headed into my second transplant feeling confident. When the call came, I was excited to wake up and finally urinate again. Instead, when the surgeon told me the transplant could not happen because my vessels were too calcified, hope turned into a deep, dark hole that took nearly a year to climb out of. I returned to dialysis immediately, facing multiple complications and emotional exhaustion. While my family and care team supported me, experiences like this reveal a critical gap in kidney care. Patients need stronger physical, psychological, and emotional support to truly recover. I was offered reconstructive surgery to make a third transplant possible but chose not to pursue it. Instead, I found peace continuing home hemodialysis and feel grateful for the quality of life I have today."

Patient voice #3: Uncertainty, Anticipatory fear, Feelings of loss

"My kidney-pancreas (K-P) transplant rejection was defined by loss and persistent uncertainty with return to hemodialysis for eight years, restructuring daily life around survival. A second

transplant, a solitary kidney since I was no longer eligible for K-P transplantation, offered renewed stability; yet, this too was temporary, resulting in another return to dialysis. These setbacks were compounded by the devastating loss of my child, just days before the second transplant rejection, intensifying grief and distress. Living now with my third transplant, each routine lab assessment carries constant fear and anticipation. Although my previous experience with dialysis helped me know what to expect, it did not make the adjustment easier; returning to dialysis after transplant failure felt like a greater loss because I was losing the health, independence, and hope that transplantation had restored. Repeated graft failure reshapes not only physical health, but psychological well-being.”

Provider Reflections:

Providers 1, 2: Moral Distress, Burnout, Risk Aversion

“After nearly 20 years caring for people with kidney disease, I still feel the weight of a failing allograft in a way that is hard to explain. I want to protect hope, but I also know my patients deserve honesty about uncertainty, graft loss, dialysis, and even death; conversations that leave me feeling torn, as every option carries emotional consequences. When a patient has trusted me and the transplant team for years, I sometimes feel responsible for outcomes I cannot fully control.”

“The pressure to satisfy regulatory metrics can unknowingly push us towards ‘safer’ patients and away from marginal donors, increasing donor kidney discards. Balancing honesty, guilt, and regulatory pressure while preserving patients’ trust becomes morally exhausting. “

Provider 3: Navigating Difficult Conversations

“When I sit with a patient facing allograft failure, I know the conversation has to hold both hope and heartbreak. I begin by focusing on what may be reversible, but also feel the urgency of preparing the patient for what may come next. That means speaking honestly about dialysis, changes to immunosuppression, possible allograft nephrectomy, and the hope of another transplant. These discussions are never just clinical; they are emotional, personal, and often frightening. I try to lead with empathy, listen carefully to what matters, and coordinate care so the patient does not feel abandoned in the hardest part of the journey.”

Provider 4: Care Transitions

“One of the hardest parts of caring for a patient with a failing allograft is helping them transition back to dialysis before the situation becomes urgent. I have seen patients come to me when kidney function is already very low, and it can be overwhelming for them to make major decisions with someone they are just beginning to trust. They may be grieving the loss of the transplant while also being asked to choose a dialysis plan quickly, creating stress for everyone involved. Earlier involvement of a general nephrologist can give patients more time, more support, and a steadier path through an already painful transition.”

Similar themes of grief, guilt, uncertainty and loss of control run through both patient and clinician reflections. While patients experience the loss physically and emotionally in daily lives, clinicians carry it as professional responsibility for an outcome they cannot fully control.

Emotional and mental health support - Gaps in Care

Allograft failure can feel like a personal loss, upending patients' identities, roles, and expectations. Much like fear of cancer recurrence, it is shaped by loss of control, chronic anticipation, disenfranchised grief (grief unacknowledged by social and medical community), and gaps in the healthcare ecosystem¹⁻⁵. Therefore, care for allograft failure should look less like a handoff between medical teams and more like a survivorship model, with repeated distress screening, and caregiver-inclusive planning beginning before transplantation, continuing across the life of the graft rather than just starting once graft failure occurs. Yet, emotional support received during hospitalization is rarely sustained after discharge, and transition to dialysis is a vulnerable time, with patients losing trusting relationships with their transplant team. Mental health access remains limited, even where screenings exist, leaving a critical window of distress unaddressed.

Potential Interventions

Evidence specific to allograft failure is limited, but models studied in the broader ESKD population may be extrapolated. A trial of cognitive behavioral therapy in transplant recipients showed greater improvement in depression scores while the control group worsened over a year suggesting the progressive nature of untreated depression⁶. A stepped telehealth collaborative-care model led to clinically significant improvements in fatigue and pain compared with controls⁷. Peer support shows promise for improved psychological well-being, self-efficacy, and engagement, although results are heterogeneous⁸.

From the provider perspective, resilience training and system-level quality improvement rather than individual blame, and employee assistance programs offering psychological support after adverse outcomes can help mitigate moral injury⁹.

Recommendations and Future Directions

Addressing the burden of allograft failure requires coordinated clinical, educational and health-system effort. Research should focus on psychosocial outcomes of graft failure, validation of distress-screening tools adapted to transplant patients, and effect of interventions on improving resilience and reducing provider burnout and moral distress. Policy must prioritize mental health access for transplant, and ESKD patients broadly. Meaningful progress can only be made with an interdisciplinary effort structurally supported by the health system and led jointly by patients and clinicians.


References:

1. Caumeil B, Bazine N, Maugendre A, Calvin S. Ecosystem Barriers and Facilitators Linked to the Fear of Cancer Recurrence: An Umbrella Review. *Int J Environ Res Public Health*. 2024 Aug 7;21(8):1041.
2. Loban K, Horton A, Robert JT, Hales L, Parajuli S, McAdams-DeMarco M, Sandal S. Perspectives and experiences of kidney transplant recipients with graft failure: A systematic review and meta-synthesis. *Transplant Rev (Orlando)*. 2023 Apr;37(2):100761. doi: 10.1016/j.trre.2023.100761. Epub 2023 Apr 13. PMID: 37120965.
3. Slominska AM, Kinsella EA, Shamseddin MK, El Wazze S, Gaudio K, Vinson A, Bugeja A, Fortin MC, Cantarovich M, Ho J, Sandal S. Identifying the Unmet Healthcare Needs of Kidney Transplant Recipients Who Experience Graft Loss: Learning From Patients' Experience. *Transplantation*. 2025 Aug 1;109(8):1425-1436.
4. Gill P, Lowes L. Renal transplant failure and disenfranchised grief: participants' experiences in the first year post-graft failure--a qualitative longitudinal study. *Int J Nurs Stud*. 2014 Sep;51(9):1271-80.
5. Ramos E, Bonnet KR, Schlundt D, Gu C, Hanson C, Gordon EJ, Concepcion BP. Patients' Perceptions of Kidney Transplant Failure and Return to Dialysis. *Kidney Medicine*. 2026;8(7):1-9.
6. Baines LS, Joseph JT, Jindal RM. Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants. *Kidney Int*. 2004 May;65(5):1937-42.
7. Jhamb M, Steel JL, Yabes JG, et al. Effects of Technology Assisted Stepped Collaborative Care Intervention to Improve Symptoms in Patients Undergoing Hemodialysis: The TĀCcare Randomized Clinical Trial. *JAMA Intern Med*. 2023;183(8):795–805.
8. Longley RM, Harnedy LE, Ghanime PM, Arroyo-Ariza D, Deary EC, Daskalakis E, Sadang KG, West J, Huffman JC, Celano CM, Amonoo HL. Peer support interventions in patients with kidney failure: A systematic review. *J Psychosom Res*. 2023 Aug;171:111379.
9. Kassam AF, Axelrod DA, Geevarghese SK. Moral injury: An unspoken burden of transplant surgery. *Am J Transplant*. 2025 Jan;25(1):32-37.

Figure Legend:

Figure 1: Shared emotional distress in the transplant care relationship following kidney allograft failure: Kidney allograft failure can lead to overlapping, but distinct distress patterns in patients²⁻⁵ and providers⁹. Relational supports for patients and institutional supports for providers can potentially buffer this shared distress.

ACCEPTED



ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

M. Baliker reports the following:

Employer: Baliker Healthcare; Consultancy: Novartis, Talaris Therapeutics, Biogen, Apellis Pharmaceuticals, Alexion Pharmaceuticals, Ardelyx, Argenx, eGenesis Bio, Inc.; Honoraria: Novartis, NIDDK, Apellis Pharmaceuticals, Alexion Pharmaceuticals, Ardelyx, Argenx and Biogen.; Advisory or Leadership Role: ESRD Network #11 Board of Directors; Kidney Health Initiative Board of Directors; NephCure; (CMS) Quality Measure Development Plan; NKF: Kidney Advocacy Committee: Chair; NKF Policy Committee: Chair, Friends of UW Health Board of Directors. Patient Centered Outcomes Research; Department of Defense Congressionally Directed Medical Research Program; The National Forum of ESRD Networks Kidney Patient Advisory Council: Chair; TRIO Board of Directors.; and Other Interests or Relationships: National Kidney Foundation; NephCure; American Association of Kidney Patients; American Kidney Fund; UNOS; Chronic Disease Coalition; Renal Support Network; ESRD Network #11; National Forum at ESRD Networks; UCSF Kidney Project Patient Advisory Council; Medical Device Innovation Consortium (MDIC) Science of Patient Input (SPI) Safety Communications. Thiotte Vulnerable Children Inc.: Transplant Recipients International Organization.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Mary Baliker

Manuscript ID: CJASN-2026-000926R1

Manuscript Title: Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives

Date of Completion: August 26, 2026

Disclosure Updated Date: August 26, 2026

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

M. Brazie reports the following:

Employer: Metropolitan Nephrology Associates, P.C.; Ownership Interest: Amazon; DXC Technologies; Advisory or Leadership Role: Fresenius Medical Care Medical Advisory Board (paid); Interwell Health Network Committee (paid); Forum of ESRD Networks Board of Directors (unpaid); ESRD Network 5 Medical Advisory Board (unpaid); and Speakers Bureau: Fresenius Medical Care, NA.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Marc F. Brazie

Manuscript ID: CJASN-2026-000926R1

Manuscript Title: Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives

Date of Completion: August 26, 2026

Disclosure Updated Date: August 26, 2026

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

D. Edwards reports the following:

Employer: ; Fresenius/NxStage Medical; Rogosin Institute; Consultancy: Fresenius ; Ardelyx; Honoraria: Ardelyx Pharma; Advisory or Leadership Role: Island Peer Review Organization Board of Directors Member - Paid; Home Paid; Forum of ESRD Networks Patent Advisory Council (KPAC) - Co-Chairperson - Not Paid; Rogosin Institute Wellness Ambassadors Program-Paid; Ardelyx Patient Advisory Council - Paid; DGCM Study Patient Advisory - Paid; and Speakers Bureau: Fresenius/NxStage.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Dawn Patricia Edwards

Manuscript ID: (CJASN-2026-000926R1)

Manuscript Title: "Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives,"

Date of Completion: August 26, 2026

Disclosure Updated Date: August 26, 2026

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

A. Howard reports the following:

Employer: Metropolitan Nephrology Associates, P.C.; Consultancy: Metropolitan Nephrology Associates, PC; and Advisory or Leadership Role: Forum of ESRD Networks, Board of Directors; Kidney Transplant Collaborative, Chairman.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Andrew D. Howard

Manuscript ID: CJSAN-2026-000926R1

Manuscript Title: Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives

Date of Completion: August 20, 2026

Disclosure Updated Date: August 20, 2026

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

D. Landry reports the following:

Employer: Kidney Care & Transplant Services of New England; Advisory or Leadership Role: I serve as President and Board of Directors member for the National Forum of ESRD Networks as well as Chair for the Medical Review Board for ESRD Network 1. I receive no financial compensation for either position.; and Other Interests or Relationships: I serve as Chair for the Medical Advisory Council at the National Forum of ESRD Networks as well as Chair for the Medical Review Board for ESRD Network 1. I receive no financial compensation for either position.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Daniel L. Landry

Manuscript ID: CJASN-2026-000926R1

Manuscript Title: Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives

Date of Completion: August 20, 2026

Disclosure Updated Date: August 20, 2026

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

P. McCowan has nothing to disclose.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Precious McCowan

Manuscript ID: CJASN-2026-000926R1

Manuscript Title: Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives

Date of Completion: August 20, 2026

Disclosure Updated Date: March 12, 2026

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

R. Sam reports the following:

Consultancy: Reatta; Chemocentryx, Unicycive, Vertex pharmaceuticals; Research Funding: astra zeneca; Bayer; Cincor, Vertex; Honoraria: Health Advances; and Other Interests or Relationships: chair of medical advisory council of the forum of ESRD networks.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Ramin Sam

Manuscript ID: CJASN-2026-000926R1

Manuscript Title: Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives

Date of Completion: August 24, 2026

Disclosure Updated Date: August 24, 2026

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

R. Sledge reports the following:

Employer: University of Missouri-St. Louis; and Advisory or Leadership Role: Missouri Kidney Program-Vice Chair of Advisory Council; The Breakfast Club St. Louis-Board Member;

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Renata Sledge

Manuscript ID: CJASN-2026-000926R1

Manuscript Title: Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives

Date of Completion: August 20, 2026

Disclosure Updated Date: August 20, 2026

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

P. Yerram reports the following:

Employer: University of Missouri; Harry S Truman Veterans Administration Hospital; Consultancy: Amgen; Fresenius; Research Funding: CareDx; Astra Zeneca, Ablative solutions; Honoraria: Amgen; Advisory or Leadership Role: Unpaid: Chair-National Forum of ESRD Networks Medical Director Advisory council (MAC), National Forum of ESRD Networks BOD member Paid: Qsource BOD member; and Speakers Bureau: Amgen.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Preethi Yerram

Manuscript ID: CJASN-2026-000926R1

Manuscript Title: Navigating the Emotional Landscape of Kidney Allograft Failure: Patient and Provider Perspectives

Date of Completion: August 26, 2026

Disclosure Updated Date: April 28, 2026